与抗抑郁药相关的治疗新出现的躁狂症:指导风险建模的元分析 潜在临床价值的药物基因组目标
相关实验视频
Updated: Jul 17, 2025

04:44
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
327
Nicolas A Nuñez1, Brandon J Coombes2, Lindsay Melhuish Beaupre2
1From the Departments of Psychiatry and Psychology.
Journal of clinical psychopharmacology
|September 8, 2023
概括
SLC6A4 5-HTTLPR多态性与双相情感障碍中抗抑郁药诱导的躁狂有关. 开发风险模型对于在双相抑郁症中安全使用抗抑郁药物至关重要.
科学领域:
- 精神病学是一个精神病学.
- 药物基因组学 药物基因组学
- 遗传学 遗传学 是一个
背景情况:
- 双极性障碍的治疗通常涉及抗抑郁药 (ADs),但存在治疗出现的躁狂 (TEM) 的风险.
- 遗传因素,如SLC6A4 5-HTTLPR多态,可能会影响TEM风险.
- 目前的药物遗传学工具对双极性抑郁症中AD的使用提供了有限的指导.
研究的目的:
- 审查SLC6A4 5-HTTLPR多态和抗抑郁药相关的TEM在双相情感障碍中的关联.
- 讨论风险分层模型的开发,以指导双相抑郁症中AD治疗决策.
主要方法:
- 一个系统的文献搜索发现了关于TEM临床和遗传风险因素的研究.
- 对七项研究 (N=1578) 的元分析使用赔率比率进行,以评估SLC6A4 5-HTTLPR多态与TEM的关联.
- 用德-西蒙尼和莱尔德模型来估计效应大小.
主要成果:
- 在SLC6A4 5-HTTLPR s等位基因与TEM (OR=1.434,P=0.0493) 之间发现了名义上显著的关联.
- 开始TEM的时间从4周到12周不等.
- 没有一项研究研究了与TEM相关的北上腺素或多巴胺载体基因关联.
结论:
- 该SLC6A4 5-HTTLPR多态性显示了与TEM的潜在联系,突出了更广泛的基因组方法的需要.
- 开发包括临床和生物因素在内的综合风险分层模型对于双相情感障碍的个性化AD治疗至关重要.
- 未来的研究应该验证风险模型,以指导双极性抑郁症的个性化医学最佳实践.
相关概念视频
Mania and Antimanic Drugs: Overview
224
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
224
Antidepressant Drugs: MAOIs and Other Agents
270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Antidepressant Drugs: Overview
555
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
555
Bipolar Disorder
83
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
83
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
Psychosis: Goals of Pharmacotherapy
165
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
165

